Man Group
NGM

Man Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Man Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-119,740
Closed -$103K – 2320
2023
Q4 		$103K Buy
+119,740
New +$105K ﹤0.01% 1983
2023
Q3 		– Sell
-95,785
Closed -$198K – 1778
2023
Q2 		$248K Buy
+95,785
New +$342K ﹤0.01% 1776
2023
Q1 		– Sell
-137,544
Closed -$636K – 1482
2022
Q4 		$690K Buy
137,544
+101,044
+277% +$633K ﹤0.01% 1423
2022
Q3 		$477K Buy
+36,500
New +$553K ﹤0.01% 1531
2022
Q2 		– Sell
-21,800
Closed -$302K – 1569
2022
Q1 		$332K Buy
21,800
+7,100
+48% +$111K ﹤0.01% 1721
2021
Q4 		$260K Buy
14,700
+1,100
+8% +$21.1K ﹤0.01% 1732
2021
Q3 		$286K Buy
+13,600
New +$299K ﹤0.01% 1662

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Man Group's NGM Position: Q1 2024 in Review

Man Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 119,740 shares — an estimated $103K sold.

Man Group first reported a position in NGM in Q3 2021 and held it in 7 quarters. The position peaked at $690K in Q4 2022. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Man Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Man Group sold 119,740 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $103K.
  • Man Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • Man Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $690K in Q4 2022.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.